Immunotherapy of cancel with a pressurized, surface reduced tumor-cell vaccine

Drug Development Research

Volumn 50, Issue 3-4, 2000, Pages 272-284

  Goldman, Yechiel ^a   Shinitzky, Meir ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Adenosine dialdehyde; Hydrostatic pressure; Lung metastasis; N acetyl L cysteine; Tumor vaccine

Indexed keywords

ACETYLCYSTEINE; ADENOSINE DIALDEHYDE; MEMBRANE PROTEIN; TUMOR ANTIGEN; TUMOR CELL VACCINE;

ANIMAL CELL; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CROSS LINKING; HUMAN; HUMAN CELL; HYDROSTATIC PRESSURE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; LUNG METASTASIS; NONHUMAN; REVIEW;

EID: 0033819539     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200007/08)50:3/4<272::AID-DDR10>3.0.CO;2-H     Document Type: Review

References (85)

1. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
2. Induction of tumour immunity with tumour cells treated with iodoacetate
3. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
4. SV40 tumor specific transplantation antigen (TSTA) in NDV lysates of SV40-transformed cells
5. Immunisation against human tumours
6. Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells
7. Cancer risk after renal transplantation in the Nordic countries, 1964-1986
8. Molecular themes in oncogenesis
9. Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment
10. High hydrostatic pressure effects in vivo: Changes in cell morphology, microtubule assembly, and actin organization
11. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
12. Promotion of replication in lymphoid cells by specific thiols and disulfides in vitro. Effects on mouse lymphoma cells in comparison with splenic lymphocytes
13. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2
14. Active immunotherapy with allogeneic tumor cell vaccines: Present status
15. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants
16. A differential polarized phase fluorometric study of the effects of high hydrostatic pressure upon the fluidity of cellular membranes
17. Induction of resistance to an isologous tumour by ultra-violet attenuated tumour cells
18. Ligand recognition by alpha beta T cell receptors
19. Effect of reactive oxygen intermediates and antioxidants on proliferation and function of T lymphocytes
20. Thiols and the immune system: Effect of N-acetylcysteine on T cell system in human subjects
21. Induction of cell-mediated immunity against B16-BL6 melanoma in mice vaccinated with cells modified by hydrostatic pressure and chemical crosslinking
22. Surface projection of murine major histocompatibility determinants induced by hydrostatic pressure and cytokines
23. Human tumor cells, modified by a novel pressure/crosslinking methodology, promote autologous lymphocyte proliferation and modulate cytokine secretion
24. The labyrinthine ways of cancer immunotherapy - T cell, tumor cell encounter: 'How do I lose thee? Let me count the ways'
25. N-acetylcysteine enhances T cell functions and T cell growth in culture
26. Gene therapy of cancer
27. Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine
28. The immunological synapse: A molecular machine controlling T cell activation
29. Creation of human tumour cells with defined genetic elements
30. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice
31. Physiological levels of hydrostatic pressure alter morphology and organization of cytoskeletal and adhesion proteins in MG-63 osteosarcoma cells
32. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?
33. The duration of antigenic stimulation determines the fate of naive and effector T cells
34. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins HSP70, HSP90, and HSP gp96
35. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma
36. Strategies for the development of vaccines to treat breast cancer
37. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein
38. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
39. Lessons from hereditary colorectal cancer
40. From TCR engagement to T cell activation: A kinetic view of T cell behavior
41. Shedding and isolation of the delta 6-desaturase system from rat liver microsomes by application of high hydrostatic pressure
42. Induction of an immunity against plasma cell sarcoma graft in the mouse BALB-c
43. Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance
44. Enhanced immunogenicity of chemically-coated syngeneic tumor cells
45. Cellular vaccine therapies for cancer
46. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines
47. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
48. Perspective on allogeneic melanoma lysates in active specific immunotherapy
49. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
50. Variations in immunogenicity of disrupted cells prepared from an adenovirus-7 hamster tumor cell line
51. Long-term disease-free survival following surgery and active specific immunotherapy with allogeneic vaccine in a patient with high-risk malignant melanoma of the vulva
52. Antimetastatic vaccination against Lewis lung carcinoma with autologous tumor cells modified to express murine interleukin 12
53. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells
54. Methods for modification of cancer cells to enhance their antigenicity
55. Immunization with chemically modified lymphoma cells
56. Augmentation of tumor immunogenicity by hydrostatic pressure and chemical crosslinking
57. Potentiation of delayed-type hypersensitivity response to syngeneic tumors in mice prevaccinated with cells modified by hydrostatic pressure and crosslinking
58. Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking
59. Galactose oxidation as a potent vaccine adjuvant strategy. Efficacy in murine models and in protection against a bovine parasitic infection
60. Promotion of tumor antigenicity in EL-4 leukemia cells by hydrostatic pressure
61. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
62. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
63. Pressure-induced depolymerization of spindle microtubules. I. Changes in birefringence and spindle length
64. Thioredoxin as a potent costimulus of cytokine expression
65. Importance of tumor cell membrane integrity and viability for cytotoxic T lymphocyte activation by cancer vaccines
66. Gamma irradiated viable tumor cells as whole-cell vaccines can stimulate in situ syngeneic antitumor cytotoxic T lymphocytes and delayed-type hypersensitivity reactivity whereas tumor cell lysates elicit only delayed-type hypersensitivity reactivity
67. Making the T cell receptor go the distance: A topological view of T cell activation
68. Cancer immunotherapy with autologous and allogeneic vaccines: A practical overview
69. Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice
70. Tumor immunology: The glass is half full
71. Peptide-binding heat shock proteins in the endoplasmic reticulum: Role in immune response to cancer and in antigen presentation
72. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world
73. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
74. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations
75. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: Tumor rejection antigen gp96 primes CD8 + T cells in vivo
76. Stress response of Escherichia coli to elevated hydrostatic pressure
77. The activity of cell-free tumour fractions in inducing immunity across a weak histocompatibility barrier
78. In vitro immunization and growth of hybridomas in serum-free medium
79. Active specific immunotherapy for metastatic colorectal carcinoma: Phase I study of an allogeneic cell vaccine plus low-dose interleukin-1 alpha
80. Galactose oxidation in the design of immunogenic vaccines
81. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes